Honz Pharmaceutical Co., Ltd. Class A

Honz Pharmaceutical Co., Ltd. Class A

SSZSE:300086
4.53
CNY
-0.14
(-3.00%)
-0.47EPS
2.44BMarket Cap
Honz Pharmaceutical Co., Ltd. Class A
SZSE:300086
(Shenzhen Stock Exchange)

Recent

price

4.53

P/E

ratio

- -

div

yld

0.68%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.78
0.68
0.82
0.69
0.91
0.91
1.05
1.48
1.96
2.24
2.05
1.86
1.19
1.53
1.04
1.02
0.74
Revenue per Share
0.35
- -
0.05
0.03
0.14
0.15
0.1
0.12
0.03
-0.06
0.02
0.02
-0.42
-0.03
-0.48
-0.51
-0.46
Basic EPS, GAAP
-0.09
-0.4
0.13
0.05
0.1
0.02
0.11
-0.3
-0.3
-0.19
-0.7
-0.46
-0.04
-0.15
-0.05
0.06
- -
Free Cash Flow per Basic Share
- -
0.13
- -
0.14
0.06
0.07
0.01
0.02
0.02
0.18
0.05
0.09
0.06
0.05
0.04
0.04
0.03
Dividend per Share
4.06
3.93
3.98
3.84
3.83
3.94
4
4.11
3.41
3.33
3.34
3.34
2.92
2.93
2.45
1.98
1.81
Book Value per Share
4.01
3.41
3.47
3.24
3.21
3.2
3.29
3.43
2.08
2.19
2.22
2.77
2.43
2.43
2
1.75
1.59
Tangible Book Value per Share
403
449
450
450
450
450
450
450
450
450
449
450
450
450
451
455
455
Basic Weighted Avg Shares
314
304
369
309
409
410
471
668
883
1,008
922
837
536
689
470
466
336
Sales/Revenue/Turnover
44.82
-11.7
-5.69
1.37
11.48
13.31
7.59
7.96
5.23
1.88
9.2
1.82
-22.66
4.54
-27.53
-34.34
-32.34
Operating Margin (%)
8
23
41
41
46
47
43
47
56
62
50
45
50
77
64
68
- -
Depreciation Expense
139
-1
23
15
62
68
46
56
13
-26
9
11
-188
-14
-215
-230
-209
Net Income, GAAP
16.31
- -
24.08
50.71
21.93
22.61
20.88
15.84
38.44
- -
30.51
48.06
- -
- -
- -
- -
- -
Effective Tax Rate (%)
44.3
-0.37
6.12
4.8
15.2
16.64
9.79
8.31
1.51
-2.62
1.01
1.31
-35.01
-1.98
-45.89
-49.37
-62.37
Profit Margin (%)
1,612
1,284
1,274
1,160
1,186
1,199
1,196
1,071
213
36
118
235
166
196
-78
-279
-347
Working Capital
- -
- -
- -
- -
- -
- -
- -
20
13
29
337
344
343
325
229
199
172
LT Debt
1,829
1,854
1,874
1,810
1,805
1,853
1,873
1,921
1,645
1,602
1,602
1,554
1,356
1,353
1,141
921
844
Total Equity
12.8
- -
0.46
0.67
2.97
3.33
1.93
2.79
1.06
- -
1.96
0.5
- -
- -
- -
- -
- -
Return on Invested Capital (%)
13.43
- -
1.36
0.03
2.26
3.76
2.91
3
0.6
- -
0.56
0.96
- -
- -
- -
- -
- -
Return on Capital (%)
13.47
-0.06
1.27
0.84
3.6
3.9
2.58
3.04
0.79
-1.74
0.62
0.73
-13.3
-1.03
-17.7
-22.84
-22.35
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
235
255
276
LT Borrowings
182
154
154
LT Finance Leases
18
18
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
455
455
455
Market Capitalization
3,746
2,685
2,444

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
269
258
220
Cash, Cash Equivalents & STI
17
16
6
Accounts Receivable, Net
41
30
25
Inventories
160
169
150
Total Current Liabilities
542
567
567
Payables & Accruals
- -
- -
- -
ST Debt
235
255
276
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-10.18%
-19.26%
Free Cash Flow
10.47%
-21.92%
-238.38%
Net Income, GAAP
-91.71%
-79.18%
6.82%
Sales/Revenue/Turnover
4.54%
-9.83%
-0.72%
Total Cash Common Dividend
67.7%
0.36%
-17.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
105
115
144
106
470
2025
112
120
- -
140
466
2026
97
48
51
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
-0.12
-0.05
-0.2
-0.48
2025
-0.02
-0.1
- -
-0.29
-0.51
2026
-0.03
-0.05
-0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -
Business
Honz Pharmaceutical Co., Ltd. (300086.SZ) engages in the research, development, manufacturing, and sales of pediatric medicines and related healthcare products primarily in China. Founded in 1994 and headquartered in Haikou, Hainan with major operations in Guangzhou, Guangdong, the company maintains five highly automated manufacturing bases across Hainan, Beijing, Hebei, Liaoning, and Guangdong, alongside a new EU GMP-standard facility under construction in Zhongshan, Guangdong. Its core products encompass children's medicines including respiratory treatments such as Ruizhiqing and Kangzhisong, digestive medicines like Kangzhitai, anti-allergic drugs, antibiotics, nutritional supplements, antibacterial and antiviral drugs, antipyretic and analgesic drugs such as Jinlishuang, adult medicines, gynecological drugs, maternal and child health products, and medical devices including masks and protective equipment; the company targets children's health markets with a focus on national branding under the Honz label. Honz Pharmaceutical recently completed the acquisition of Zhongshan Care for Baby Daily Products Co., Ltd. from Hainan Hongshi Investment Co., Ltd. in August 2024 to bolster its maternal and child portfolio, while its controlling shareholder plans to increase its stake by up to 2% through a CNY100 million investment; the firm also earned recognitions such as the 2023 Hainan Top 40 Manufacturing Enterprises and Excellent ESG Case awards, alongside ongoing implementation of its Children's Health Global Strategy.